That cements their confidence in the success of the trials
four sites actively recruiting for the MagSense® HER2
breast cancer study with multiple patients having completed the study. We now start 2022 having moved
into a new facility that greatly expands our R&D capabilities and adds manufacturing capacity to support
the commercial development of our nanoparticle products.
Adding, “We feel the study is progressing in a positive direction and will provide material updates as they
arise.”
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-38
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
